Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Antibe Therapeutics Inc. has sought an extension of its stay of proceedings under the CCAA to May 24, 2024, as the company navigates regulatory discussions with the FDA regarding a clinical trial hold. This extension is crucial for Antibe as it continues to develop its innovative pipeline, including a potentially safer alternative to opioids and NSAIDs for pain treatment. The court has yet to decide on the stay extension, a decision that will be pivotal for the company’s immediate operations and future clinical advancements.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
